Compare · DICE vs NVO
DICE vs NVO
Side-by-side comparison of DICE Therapeutics Inc. (DICE) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DICE and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 300.9x DICE ($608.6M).
- NVO has hit the wire 8 times in the past 4 weeks while DICE has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 12 for DICE).
- Company
- DICE Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $47.56+0.12%
- $41.01-4.51%
- Market cap
- $608.6M
- $183.15B
- 1M return
- -
- -10.44%
- 1Y return
- -
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 8
- Recent ratings
- 12
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DICE
- SEC Form 15-12G filed by DICE Therapeutics Inc.
- SEC Form EFFECT filed by DICE Therapeutics Inc.
- SEC Form 4 filed by Ra Capital Management, L.P.
- SEC Form SC 13D/A filed by DICE Therapeutics Inc. (Amendment)
- SEC Form 4: Tetlow Sharon returned 49,841 shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Simson Jake
- SEC Form 4: Scopa James Paul returned 40,921 shares to the company, closing all direct ownership in the company
- SEC Form 4: Robertson Scott M. returned 198,000 shares to the company, closing all direct ownership in the company
- SEC Form 4: Scheller Richard H returned 8,427 shares to the company, closing all direct ownership in the company
- SEC Form 4: Timothy Lu returned 152,285 shares to the company, closing all direct ownership in the company
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care